New daily diabetes pill that helps with weight loss launches in UK pharmacies
Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) launches in UK pharmacies on private prescription, making Britain the first European country to offer it, while pharmacists warn of counterfeit risks.
Intelligence analysis by Llama
Eli Lilly's oral GLP-1 pill Foundayo, already approved by the MHRA earlier this month, is now available in UK pharmacies via private prescription. Pharmacists welcome the option for patients who cannot use jabs but flag a counterfeit GLP-1 market and a postcode lottery for NHS weight-management care.
A new once-a-day pill called Foundayo that helps people with diabetes and also helps them lose weight is now for sale in pharmacies in the UK. It's like a regular tablet you swallow each morning. Doctors hope it will help people who don't like the usual weight-loss injections.
Analysis
Eli Lilly's oral bet
The launch of Foundayo marks a deliberate expansion by Eli Lilly beyond injectable GLP-1 therapies into a once-daily oral formulation. According to Khalil Asmar, the vice-president of cardiometabolic health at Lilly Northern Europe, the company is "pleased" the pill offers "another oral treatment option for eligible UK patients alongside licensed injectable treatments." The drug is licensed for adults with a BMI of 30 or above, or for those with a BMI of 27 to 30 who also carry a weight-related condition, and can be used to improve blood sugar levels in patients with poorly controlled type 2 diabetes. Its convenience profile — taken once a day at any time, with no food or water restrictions — is the central commercial pitch, broadening the universe of patients willing or able to start a GLP-1 regimen.
The £250,000 Northampton seizure
Counterfeit risk is shadowing the rollout. The article notes that the MHRA seized £250,000-worth of unlicensed weight-loss pens and ingredients from a factory in Northampton last year, and Eli Lilly is suing various suppliers it accuses of participating in an illegal hidden market for its drugs. Pharmacists argue that pills are easier to fake than injectables, which require cold-chain handling and pre-filled devices, so the proliferation of counterfeit oral GLP-1s is a near-term concern. The National Pharmacy Association's Henry Gregg framed the moment as "another significant day" while urging patients to access treatment only through safe and regulated pharmacies, a clear signal that the sector sees enforcement, not just availability, as part of the rollout story.
A private-prescription first, an NHS decision later
Foundayo is initially available only through private prescription. Eli Lilly says it is working with the National Institute for Health and Care Excellence on an assessment for a potential NHS rollout in England, but no timeline is given in the article. Gregg's critique of a "postcode lottery" for weight management services via GPs underlines the access gap the company hopes to position its product around. The MHRA also approved a tablet form of Wegovy in June, meaning the UK now has two oral GLP-1 options and is setting the regulatory pace in Europe for this drug class — a competitive signal for Novo Nordisk as much as a commercial one for Lilly.
Key points
- Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1, is now available in UK pharmacies on private prescription.
- The MHRA approved the drug earlier this month, making the UK the first European country to offer it.
- It is licensed for adults with a BMI of 30 or above, or 27 to 30 with a weight-related condition, and for type 2 diabetes blood-sugar control.
- Pharmacists welcomed the option for patients who cannot use jabs but warned of growing counterfeit and unlicensed GLP-1 products.
- Eli Lilly is working with NICE on a potential NHS rollout in England.
If Foundayo proves easy to prescribe and tolerate, it could meaningfully widen the pool of patients who start a GLP-1 regimen, particularly those who refuse injections, and give NICE the evidence base to green-light a public rollout. A successful NHS pathway would also undercut the black market that has grown up around injectable weight-loss products.
Pills are cheaper and easier to fake than injectables, so the counterfeit pipeline that the MHRA and Eli Lilly are already pursuing could expand quickly, exposing patients to unregulated doses. A long or restrictive NICE assessment, meanwhile, would leave Foundayo accessible only to those who can pay privately, deepening the postcode lottery that pharmacists have already flagged.
Market signals
- LLY A UK retail launch extends Lilly's oral GLP-1 footprint and adds a new revenue stream, though private-only availability tempers the near-term size of the opportunity.
AI-generated analysis of potential market relevance. Not financial advice.
